Regeneron Pharmaceuticals Inc. (ISIN: US7739031091) stock dropped 3.6% to $746.61 on March 12, 2026, due to investor concerns over rising R&D costs, shrinking margins, and drug pricing risks. The company reported a 42.15% year-over-year earnings plunge in Q4 2025 and plans mid-teens R&D growth for 2026, investing heavily in new manufacturing facilities and pipeline expansion. Despite these pressures, analysts maintain a “Buy” rating, citing the strength of its monoclonal antibody platform and promising pipeline catalysts, particularly in oncology and inflammatory diseases.
Regeneron Pharmaceuticals Inc Stock (ISIN: US7739031091) Faces Pressure Amid R&D Surge and Margin Squeeze
Regeneron Pharmaceuticals Inc. (ISIN: US7739031091) stock dropped 3.6% to $746.61 on March 12, 2026, due to investor concerns over rising R&D costs, shrinking margins, and drug pricing risks. The company reported a 42.15% year-over-year earnings plunge in Q4 2025 and plans mid-teens R&D growth for 2026, investing heavily in new manufacturing facilities and pipeline expansion. Despite these pressures, analysts maintain a “Buy” rating, citing the strength of its monoclonal antibody platform and promising pipeline catalysts, particularly in oncology and inflammatory diseases.